Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707990 · ClinicalTrials.gov registry record · Phase 1
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT03707990 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 88 participants.
The verdict
NCT03707990, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts. If participants take part in Part 1, they will either get a single dose of NNC0165-1875 or a "dummy" medicine (placebo). If participants take part in Part 2, they will either get a single dose of NNC0165-1875 or "dummy" medicine and also a single dose of semaglutide. Which treatment participants get is decided by chance. For Part 1 participants will get 1 injection. For Part 2 participants will get 2 injections. A study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. The study will last for about 9 weeks. Participants will have 7 visits to the clinic with the study doctor.
Interventions
- DRUG Semaglutide
- DRUG NNC0165-1875
- DRUG Placebo (NNC0165-1875)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2019-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03707990
The ClinicalTrials.gov registry entry for NCT03707990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT03707990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03707990 about?
NCT03707990 is a clinical study titled "A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese". The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts. If participants take part in Part 1, they will either get a single dose of NNC0165-1875 or a "dummy" medicine...
What is the current status of trial NCT03707990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2018-10-15. Estimated completion is 2019-08-13.
What interventions are being tested in trial NCT03707990?
The interventions under investigation include: Semaglutide (DRUG), NNC0165-1875 (DRUG), Placebo (NNC0165-1875) (DRUG).
Who is sponsoring clinical trial NCT03707990?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.